Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 14, 2008

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name:
PODESTA GROUP, INC
2. Address: 1001 G STREET, NW SUITE 900 EAST, WASHINGTON, DC 20001
Principal place of business (if different from line 2):
4. Contact Name: KIMBERLEY FRITTS Telephone: 2023931010 E-mail (optional): LOBBYING@PODESTA.COM
Senate ID #: 31680-2156 House ID #:
7. Client Name: Self
AMGEN
TYPE OF REPORT
8. Year 2007 Midyear (January 1 - June 30): OR Year End (July 1 - December 31): 🛛
9. Check if this filing amends a previously filed version of this report:
10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:
INCOME OR EXPENSES
Complete Either Line 12 OR Line 13
12. Lobbying Firms
INCOME relating to lobbying activities for this reporting period was:
Less than \$10,000:
\$10,000 or more: X => Income (nearest \$20,000): 120,000.00
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).
13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000:
\$10,000 or more: => Expenses (nearest \$20,000):
14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Page 1

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: CPT (one per page)
- 16. Specific lobbying issues:

Intellectual property and process patent issues S. 1145, Patent Reform Act of 2007, entire bill H. R. 1908, Patent Reform Act of 2007, entire bill

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES Patent & Trademark Office (PTO) SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAIERLEIN, DANIELE Covered Official Position (if applicable): N/A Name: COHEN, SHARON Covered Official Position (if applicable): N/A Name: HAGEN, COURTNEY Covered Official Position (if applicable): N/A Name: JAMES, CLAUDIA Covered Official Position (if applicable): N/A Name: KAUDERS, ANDREW Covered Official Position (if applicable): SR. ADV. SEN. MENENDEZ; ED, HOUSE DEM CAUCUS Name: MORRA, ELIZABETH Covered Official Position (if applicable): N/A Name: PODESTA, ANTHONY Covered Official Position (if applicable): N/A Name: POLAK, ANN MARIÈ Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed

- 15. General issue area code: HCR (one per page)
- 16. Specific lobbying issues:

Follow-on biologics S. 623, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1980, Food and Drug Administration Amendments Act of 2007 H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 1505, Affordable Biologics for Consumers Act, follow-on biologics FDA Drug Safety Oversight S. 1082, Prescription Drug User Fee Amendments, drug safety provisions H. R. 2900, Food and Drug Administration Revitalization Act, drug safety provisions

17. House(s) of Congress and Federal agencies contacted: Food & Drug Administration (FDA) HOUSE OF REPRESENTATIVES SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAIERLEIN, DANIELE Covered Official Position (if applicable): N/A Name: BRATHWAITE, PAÙL Covered Official Position (if applicable): EXEC. DIR., CONGRESSIONAL BLACK CAUCUS Name: COHEN, SHARON Covered Official Position (if applicable): N/A Name: GERARD, RANDALL Covered Official Position (if applicable): N/A Name: HAGEN, COURTNEY Covered Official Position (if applicable): N/A Name: JAMES, CLAUDIA Covered Official Position (if applicable): N/A Name: KAUDERS, ANDREW Covered Official Position (if applicable): SR. ADV. SEN. MENENDEZ; ED, HOUSE DEM CAUCUS Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A Name: POLAK, ANN MARIE Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON Name: SCOFIELD, JOHN Covered Official Position (if applicable): COMM. DIR., HOUSE APPROPS. COMMITTEE

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as

- 15. General issue area code: MMM (one per page)
- 16. Specific lobbying issues:
- S. 2499, Medicare, Medicaid, and SCHIP Extension Act of 2007 Medicare coverage and reimbursement of Erythropoiesis-Stimulating Agents H. R. 3162, Children's Health and Medicare Protection Act of 2007 S. 1893, Children's Health Insurance Program Reauthorization Act of 2007 S. 976, Genomics and Personalized Medicine Act of 2007
- 17. House(s) of Congress and Federal agencies contacted: Centers For Medicare and Medicaid Services (CMS) Executive Office of the President (EOP) HOUSE OF REPRESENTATIVES Health & Human Services, Dept of (HHS) SENATE
- 18. Name of each individual who acted as a lobbyist in this issue area:

Name: BAIERLEIN, DANIELE

Covered Official Position (if applicable): N/A

Name: BRATHWAITE, PAÙL

Covered Official Position (if applicable): EXEC. DIR., CONGRESSIONAL BLACK CAUCUS

Name: COHEN, SHARON

Covered Official Position (if applicable): N/A

Name: GERARD, RANDALL

Covered Official Position (if applicable): N/A

Name: HAGEN, COURTNEY

Covered Official Position (if applicable): N/A

Name: HUNTLEY, AMANDA

Covered Official Position (if applicable): N/A Name: KAUDERS, ANDREW

Covered Official Position (if applicable): SR. ADV. SEN MENENDEZ; ED, HOUSE DEM CAUCUS

Name: PODESTA, ANTHONY
Covered Official Position (if applicable): N/A

Name: POLAK, ANN MARIE

Covered Official Position (if applicable): LEG. CORRESPONDENT FOR REP. MIKE FERGUSON

Name: SCOFIELD, JOHN

Covered Official Position (if applicable): COMM. DIR., HOUSE APPROPS. COMMITTEE

Name: SLENZAK, LANTIE

Covered Official Position (if applicable): LEGISLATIVE DIRECTOR, REP. GENE GREEN

Name: URBAN, HEATHER

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: KIMBERLEY FRITTS, CEO -

Registrant Name: PODESTA GROUP, INC Client Name: AMGEN

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

Name: BRATHWAITE, PAUL Name: URBAN, HEATHER

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Feb 14, 2008

Printed Name and Title: -